Bayer to acquire Vividion Therapeutic for $1.5bn
German pharmaceutical firm Bayer has agreed to acquire Vividion Therapeutic to strengthen its drug discovery capabilities. Vividion Therapeutics uses novel discovery technologies to develop therapies for patients with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.